120 related articles for article (PubMed ID: 16406142)
1. Dimerization of the melanocortin 4 receptor: a study using bioluminescence resonance energy transfer.
Nickolls SA; Maki RA
Peptides; 2006 Feb; 27(2):380-7. PubMed ID: 16406142
[TBL] [Abstract][Full Text] [Related]
2. Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides.
Nijenhuis WA; Wanders N; Kruijtzer JA; Liskamp RM; Gispen WH; Adan RA
Eur J Pharmacol; 2004 Jul; 495(2-3):145-52. PubMed ID: 15249163
[TBL] [Abstract][Full Text] [Related]
3. Functional complementation of high-efficiency resonance energy transfer: a new tool for the study of protein binding interactions in living cells.
Molinari P; Casella I; Costa T
Biochem J; 2008 Jan; 409(1):251-61. PubMed ID: 17868039
[TBL] [Abstract][Full Text] [Related]
4. Monitoring the activation state of insulin/insulin-like growth factor-1 hybrid receptors using bioluminescence resonance energy transfer.
Blanquart C; Gonzalez-Yanes C; Issad T
Mol Pharmacol; 2006 Nov; 70(5):1802-11. PubMed ID: 16926280
[TBL] [Abstract][Full Text] [Related]
5. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
Fleck BA; Chen C; Yang W; Huntley R; Markison S; Nickolls SA; Foster AC; Hoare SR
Biochemistry; 2005 Nov; 44(44):14494-508. PubMed ID: 16262250
[TBL] [Abstract][Full Text] [Related]
6. Melanocortin receptors form constitutive homo- and heterodimers.
Mandrika I; Petrovska R; Wikberg J
Biochem Biophys Res Commun; 2005 Jan; 326(2):349-54. PubMed ID: 15582585
[TBL] [Abstract][Full Text] [Related]
7. Multimeric alpha-MSH has increased efficacy to activate the melanocortin MC4 receptor.
Tiesjema B; Merkestein M; Garner KM; de Krom M; Adan RA
Eur J Pharmacol; 2008 May; 585(1):24-30. PubMed ID: 18378226
[TBL] [Abstract][Full Text] [Related]
8. Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the melanocortin system.
Adan RA
Trends Pharmacol Sci; 2006 Apr; 27(4):183-6. PubMed ID: 16500715
[TBL] [Abstract][Full Text] [Related]
9. Peptoid-peptide hybrids as potent novel melanocortin receptor ligands.
Kruijtzer JA; Nijenhuis WA; Wanders N; Gispen WH; Liskamp RM; Adan RA
J Med Chem; 2005 Jun; 48(13):4224-30. PubMed ID: 15974575
[TBL] [Abstract][Full Text] [Related]
10. Assembly and signaling of CRLR and RAMP1 complexes assessed by BRET.
Héroux M; Breton B; Hogue M; Bouvier M
Biochemistry; 2007 Jun; 46(23):7022-33. PubMed ID: 17503773
[TBL] [Abstract][Full Text] [Related]
11. Substituted NDP-MSH peptides paired with mutant melanocortin-4 receptors demonstrate the role of transmembrane 6 in receptor activation.
Fleck BA; Ling N; Chen C
Biochemistry; 2007 Sep; 46(37):10473-83. PubMed ID: 17713970
[TBL] [Abstract][Full Text] [Related]
12. Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms.
Xiang Z; Pogozheva ID; Sorenson NB; Wilczynski AM; Holder JR; Litherland SA; Millard WJ; Mosberg HI; Haskell-Luevano C
Biochemistry; 2007 Jul; 46(28):8273-87. PubMed ID: 17590021
[TBL] [Abstract][Full Text] [Related]
13. Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.
Bakshi RK; Hong Q; Tang R; Kalyani RN; Macneil T; Weinberg DH; Van der Ploeg LH; Patchett AA; Nargund RP
Bioorg Med Chem Lett; 2006 Mar; 16(5):1130-3. PubMed ID: 16364639
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
15. Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for receptor activation.
Hogan K; Peluso S; Gould S; Parsons I; Ryan D; Wu L; Visiers I
J Med Chem; 2006 Feb; 49(3):911-22. PubMed ID: 16451057
[TBL] [Abstract][Full Text] [Related]
16. Kinetic evidence for tandemly arranged ligand binding sites in melanocortin 4 receptor complexes.
Kopanchuk S; Veiksina S; Mutulis F; Mutule I; Yahorava S; Mandrika I; Petrovska R; Rinken A; Wikberg JE
Neurochem Int; 2006 Oct; 49(5):533-42. PubMed ID: 16764968
[TBL] [Abstract][Full Text] [Related]
17. Novel, isotype-specific sensors for protein kinase A subunit interaction based on bioluminescence resonance energy transfer (BRET).
Prinz A; Diskar M; Erlbruch A; Herberg FW
Cell Signal; 2006 Oct; 18(10):1616-25. PubMed ID: 16524697
[TBL] [Abstract][Full Text] [Related]
18. The constitutive activity of melanocortin-4 receptors in cAMP pathway is allosterically modulated by zinc and copper ions.
Link R; Veiksina S; Tahk MJ; Laasfeld T; Paiste P; Kopanchuk S; Rinken A
J Neurochem; 2020 May; 153(3):346-361. PubMed ID: 31792980
[TBL] [Abstract][Full Text] [Related]
19. Dimerizations of the wallaby gonadotropin-releasing hormone receptor and its splice variants.
Cheung TC; Hearn JP
Gen Comp Endocrinol; 2005 Dec; 144(3):280-8. PubMed ID: 16102759
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism.
Proneth B; Xiang Z; Pogozheva ID; Litherland SA; Gorbatyuk OS; Shaw AM; Millard WJ; Mosberg HI; Haskell-Luevano C
Chem Biol Drug Des; 2006 Mar; 67(3):215-29. PubMed ID: 16611215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
